Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

154.68 -11.16 (-6.73%)
Streaming Delayed Price Updated: 2:49 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Why Johnson & Johnson Stock Is Sinking Today
Via The Motley Fool
Topics Bankruptcy Lawsuit Stocks
Exposures Financial Legal US Equities
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Wall Street Inches Up Ahead Of Tariff Day: What's Driving Markets Tuesday?
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends. 
Via Chartmill
Why Johnson & Johnson (JNJ) Shares Are Falling Today
Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ) fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield... 
Via StockStory
Topics Bankruptcy Lawsuit
Exposures Financial Legal
US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High
The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and... 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-04-01: top gainers and losers in today's session. 
Via Chartmill
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan
The company says it will return to the civil court system to handle tens of thousands of claims its talc-based products caused cancer. 
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
Exposures Financial Legal
US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims
Johnson & Johnson will fight talc lawsuits in court after its subsidiary's bankruptcy plan was denied, reversing $7 billion in legal reserves. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Federal Judge Rejects Johnson & Johnson Bankruptcy Strategy, Paving Way for Talc Victims to Seek Justice in Trial Courts
From Beasley Allen Law Firm
Via Business Wire
2 Value Stocks I'm Buying Right Now
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Johnson & Johnson to Return to Tort System to Defeat Meritless Talc Claims
From Johnson & Johnson
Via Business Wire
Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification. 
Via Benzinga
Topics ETFs Economy
Exposures Economy Interest Rates
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
3 Relatively Safe Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, March 28
Looking for further upside into wave {v}, as we appear to be missing one leg higher to complete the five-wave move subdivision. 
Via Talk Markets
Topics Stocks / Equities
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
2 Reasons to Like JNJ and 1 to Stay Skeptical
Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19. 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
What Rare Earth Minerals Does Ukraine Have?
Ukraine is recognized as a country with significant mineral wealth, including a variety of rare earth elements (REEs) and other critical minerals. These resources have drawn global attention,... 
Via MarketMinute
Topics Economy Electric Vehicles Emissions
Exposures Economy Electric Vehicles Fossil Fuels
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
2 Recession-Proof Dividend Stocks to Buy and Hold
Via The Motley Fool
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib. 
Via Benzinga
Kenvue Stock In Focus As TOMS Capital Reportedly Pushes For Sale Or Breakup: Will It Shift Retail Mood?
Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of... 
Via Stocktwits
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints. 
Via Benzinga
Exposures Product Safety
Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery
Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American manufacturing, research, and development, creating high-tech jobs and... 
Via Benzinga
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
From Johnson & Johnson
Via Business Wire
Two Sectors Just Tried And Failed - And That’s Great For Us
Technology and healthcare have both tried for a breakout and failed, courtesy of massive economic forces rocking the boat. 
Via Talk Markets
Topics Stocks / Equities
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.